Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)
Launched by HEIDELBERG ENGINEERING GMBH · May 24, 2016
Trial Information
Current as of May 15, 2025
Terminated
Keywords
ClinConnect Summary
This prospective, single-arm clinical multicenter study intends to measure normal structural parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the macula using the Heidelberg Spectralis OCT device. This study is conducted in African-American descent volunteers. The main goal of the study is to provide the range of these structural parameters in normal eyes. The study will include at least 240 normal volunteers; up to 10 study sites will recruit subjects. Overall an approximately equal age distribution from 18 to 90 years and an approximately equal number o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able and willing to undergo the test procedures, give consent, and to follow instructions.
- • Signed informed consent
- • Age ≥18 to 90.
- • Healthy eye without prior intraocular surgery (except cataract surgery and Laser in Situ Keratomileusis) and without clinically significant vitreal, retinal or choroidal diseases, clinically significant diabetic retinopathy (subject may have diabetes), or disease of the optic nerve. Small drusen are acceptable in older subjects.
- • Black or African-American decent (self-reported)
- • Negative history of glaucoma (not including family history)
- • Intraocular pressure ≤21mmHg.
- • Best corrected visual acuity ≥20/40.
- • Refraction between +6 and -6 diopters and astigmatism ≤ 2 diopters.
- • Axial length ≤ 26.0 mm (by optical biometry)
- • Normal visual field with Glaucoma Hemifield Test and Mean Deviation within normal limits or not abnormal visual field by judgment of the ophthalmologist / optometrist
- • Clinically normal appearance of the optic disc, with normal appearing neuroretinal rim with respect to color and shape. The optic disc is examined ophthalmoscopically and by evaluation of stereo photographs.
- • If both eyes are eligible, both eyes enter the study.
- Exclusion Criteria:
- • Vulnerable subjects (as defined in ISO 14155 GCP) with the exception of employees of the site, and, if applicable, students of the respective university. Staff that is listed on the delegation form are excluded from participation.
- • Subjects unable to read or write
- • Unreliable visual field. The reliability indices should be used as guide as well as the perimetrist's notes.
- • Unusable disc stereo photos.
- • Inability to undergo the tests.
- • Insufficient quality of Spectralis OCT images (this is not determined until after Spectralis OCT examination, and is an unusual circumstance).
- Minimum requirements are:
- • Retina completely included in image frame,
- • Quality Score ≥ 20 in the stored ART mean images, and
- • For ONH-R scan: Center position error ≤ 100 μm.
About Heidelberg Engineering Gmbh
Heidelberg Engineering GmbH is a leading global developer of innovative diagnostic and therapeutic solutions for eye care. With a strong focus on advancing ophthalmic technology, the company specializes in high-resolution imaging systems, data management software, and integrated clinical workflows that enhance patient care and streamline clinical processes. Committed to research and development, Heidelberg Engineering collaborates with healthcare professionals and institutions worldwide to improve understanding and treatment of ocular diseases. Through its dedication to quality and innovation, the company aims to empower clinicians with the tools necessary for accurate diagnosis and effective patient management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
New York, New York, United States
La Jolla, California, United States
Santa Monica, California, United States
Mount Dora, Florida, United States
Chicago, Illinois, United States
Jamaica, New York, United States
Valley Stream, New York, United States
Patients applied
Trial Officials
Balwantray Chauhan, OD
Principal Investigator
Department of Ophthalmology and Visual Sciences Dalhousie University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials